



**BBCIC**

Biologics & Biosimilars  
Collective Intelligence Consortium

QUARTERLY



## A Note from the Executive Director

Fall always becomes a time for contemplation for me. The leaves start changing and the world around begins to prepare for winter. It's a time to reflect on how far we have come over the year, from the growth of spring to the busy intensity of summer, to the sigh of fall. While the great work of BBCIC doesn't ebb or flow with the seasons (it's pretty intense all the time!), there is still a sense of seasonality as fall scientific and professional meetings occur, and submission deadlines in anticipation for spring meetings march ever closer.

[Read the full letter.](#)

## In this Issue

- » Current Research
- » Abstract Tracker
- » Manuscript Tracker
- » Upcoming Research
- » Research Planning
- » Publications to Date
- » Fundraising
- » Research Dashboard

## Current Research

### G-CSF Comparative Safety and Effectiveness

**Status Update – October 2021:** Our de novo program designed to identify patient cohorts and extract de-identified person-level data according to the protocol is undergoing testing with the lead study partner data with promising results from an initial test run. Once testing is complete, we will distribute the finalized code to BBCIC Research Partners to extract data and build the full data set. Meanwhile, we will finalize the manuscript describing the challenges we faced and solutions we implemented to accurately identify the study cohorts. This manuscript will be submitted to Medical Care or another journal with health-services or methodology-based readership.

### Treatment and Switching Patterns in Rheumatoid Arthritis

**Status Update – October 2021:** A workgroup has been convened to plan a descriptive analysis of treatment patterns and switching among RA patients treated with immunomodulating biologics (e.g., TNFi, JAKi). We are finalizing the study proposal for Science Committee review, followed by development of a detailed protocol.

### Data Fitness and Capabilities

**Status Update – October 2021:** A survey is in preparation to take a deeper dive into existing network partner data resources that extend beyond the Sentinel Common Data Model, and follow-up evaluation of the external data sources who responded to the initial workgroup questionnaire.

### Utilization Analyses

**Status Update – October 2021:**

**Trastuzumab** – a preliminary analysis has been completed describing utilization patterns of HER2-inhibitor products and two abstracts were accepted for poster presentation at ASCO Quality Care 2021 and AMCP Nexus 2021. The abstract accepted at AMCP Nexus received a PLATINUM RIBBON and was one of only five abstracts selected for podium presentation during the meeting!!

**Insulins** – code has been updated to include a modified algorithm (Klompas, et al. 2013) to classify people with diagnoses for both Type 1 and Type 2 diabetes

## Upcoming Research

The BBCIC Science Committee will be meeting in November to review all Research Topic Request proposals and will vote to establish the 2022 research priority list.

### Utilization Analyses

**Anti-Inflammatory Agents** – a workgroup will be convened to redesign our past utilization analysis to better define patient cohorts and treatment patterns. All available tumor necrosis factor-alpha inhibitors (TNFi), non-TNFi, and Janus Kinase (JAK) inhibitors will be included.

**Rituximab** – a workgroup will be convened to design an analysis of utilization patterns and characteristics of patients treated with

in their record. Data analysis is underway and we will compare these results to prior analyses without the algorithm in which patients with both diagnoses were excluded.

**Bevacizumab** – a workgroup has begun designing a study of utilization patterns and characteristics of patients treated with bevacizumab for both cancer (on-label) and ophthalmology (off-label) indications. The study plan is near final and data specifications are in preparation.

rituximab for cancer, multiple sclerosis, and rheumatoid arthritis.

## Publications to Date: 2021

Utilization patterns and characteristics of users of biologic anti-inflammatory agents in a large, US commercially insured population

- Mendelsohn A.  
*Pharmacol Res Perspect*

Patient characteristics and utilization patterns of short-acting recombinant granulocyte colony-stimulating factor (G-CSF) biosimilars compared to their reference product

- Mendelsohn A.B.  
*Drugs – RWO*

Descriptive Analysis of First-Cycle Prophylactic Use of G-CSF in Patients with Breast or Small Cell Lung Cancer Treated with High Neutropenia Risk Chemotherapy

- Pawloski P.A.  
*J Natl Compr Canc Netw*

## Abstract Tracker

| Abstract                      | Planned | Analysis in Progress | Analysis Complete | Prepared | Reviewed | Submitted | Accepted | Presented | Meeting                |
|-------------------------------|---------|----------------------|-------------------|----------|----------|-----------|----------|-----------|------------------------|
| Oncology Data Feasibility     |         |                      |                   |          |          |           |          |           | AMCP 2021              |
| Insulins Utilization          |         |                      |                   |          |          |           |          |           | AMCP 2021              |
| Oncology Data Feasibility     |         |                      |                   |          |          |           |          |           | ICPE 2021              |
| Trastuzumab Review - Cancer   |         |                      |                   |          |          |           |          |           | AMCP Nexus 2021        |
| Bevacizumab Review - AMD      |         |                      |                   |          |          |           |          |           | AMCP Nexus 2021        |
| Trastuzumab Utilization       |         |                      |                   |          |          |           |          |           | ASCO Quality Care 2021 |
| Trastuzumab Utilization       |         |                      |                   |          |          |           |          |           | AMCP Nexus 2021        |
| Infliximab Review - Switching |         |                      |                   |          |          |           |          |           | TBD                    |
| Rituximab Review - RA         |         |                      |                   |          |          |           |          |           | TBD                    |
| Rituximab Review - MS         |         |                      |                   |          |          |           |          |           | TBD                    |
| Rituximab Review - Cancer     |         |                      |                   |          |          |           |          |           | TBD                    |

## Manuscript Tracker

| Manuscript Topic              | Planned | In Preparation | Draft Complete | BBCIC Review | Submitted | Peer-Review | Accepted | Published | Target Journal            |
|-------------------------------|---------|----------------|----------------|--------------|-----------|-------------|----------|-----------|---------------------------|
| G-CSF Scoping Review          |         |                |                |              |           |             |          |           | Supportive Care in Cancer |
| G-CSF CER Protocol            |         |                |                |              |           |             |          |           | BMJ Open                  |
| G-CSF Algorithm - Methods     |         |                |                |              |           |             |          |           | TBD                       |
| Trastuzumab Review - Cancer   |         |                |                |              |           |             |          |           | TBD                       |
| Bevacizumab Review - AMD      |         |                |                |              |           |             |          |           | TBD                       |
| Infliximab Review - Switching |         |                |                |              |           |             |          |           | TBD                       |
| Rituximab Review - RA         |         |                |                |              |           |             |          |           | TBD                       |
| Rituximab Review - MS         |         |                |                |              |           |             |          |           | TBD                       |
| Rituximab Review - Cancer     |         |                |                |              |           |             |          |           | TBD                       |
| Oncology Data Fitness         |         |                |                |              |           |             |          |           | TBD                       |
| G-CSF Final Results           |         |                |                |              |           |             |          |           | TBD                       |

## Research Planning

### Trastuzumab Comparative Safety and Effectiveness – Planning

Background and Purpose: With five trastuzumab biosimilars now available in the United States, one of the top BBCIC research priorities is to conduct a comparative safety and effectiveness study across trastuzumab products. A Research Team will be assembled to begin planning this study, including an

assessment of data needs (in conjunction with the Data Fitness and Capabilities work currently underway), and an initial study design and framework. A call for current BBCIC volunteers to participate in this important planning effort is forthcoming!

### Development and Validation of Coding Algorithms – Planning

Background and Purpose: Conducting observational research using administrative claims is both powerful and challenging. One challenge is in identifying patient cohorts, clinical outcomes, and treatment regimens using data collected for purposes of billing and reimbursement. There is a need in the observational research community for robust, validated algorithms to reliably identify those elements that are so essential to conducting meaningful research. We have an opportunity to collaborate with our colleagues at IMEDS to contribute to this shared interest. A call for current BBCIC volunteers to participate in planning this new initiative is forthcoming!

### Patient Engagement Strategy


BBCIC is excited to begin developing a strategy to engage patients throughout all aspects of our research! With guidance from two of our patient advocacy representatives, a team of BBCIC volunteers will begin preparing a plan to build our network of patients and patient groups and identify opportunities to include those important voices in our work. Current BBCIC Participants: stay tuned for a call for volunteers to join this effort!

### Fundraising:


GivingTuesday with AMCP Foundation Nov. 30 is GivingTuesday, the global generosity movement unleashing the power of people and organizations to transform their communities and their world. During this time, AMCP Foundation will be encouraging donations to support their research agenda and the next generation of managed care pharmacists. Let's lend our support to AMCP Foundation and [make a gift today.](#)

## Research Dashboard

# BBCIC Research – 5 Years of Progress



# BBCIC Research – 2021 So Far



2020 Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) | [bbcic.org](http://bbcic.org)

Address  
675 N Washington Street  
Suite 220  
Alexandria, VA 22314

[Unsubscribe me from this email.](#)